IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein

Silvia Gaggero1, Jonathan Martinez-Fabregas2, Adeline Cozzani1

  • 1Inserm UMR1277, CNRS UMR9020-CANTHER, Université de Lille, Lille University Hospital, Lille, France.

Science Immunology
|December 2, 2022
PubMed

Insights

Tumor acidity impairs interleukin-2 (IL-2) immune signaling. A novel IL-2 variant, Switch-2, overcomes this pH limitation, enhancing T cell immunity and tumor rejection with reduced toxicity.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • Cytokine-receptor interactions govern immune responses.
  • Extracellular space physicochemical properties' impact on cytokine signaling is not fully understood.
  • Interleukin-2 (IL-2) is crucial for T cell immunity.

Purpose of the Study:

  • To investigate the influence of tumor microenvironment pH on IL-2 signaling.
  • To develop a pH-resilient IL-2 variant for improved cancer immunotherapy.

Main Methods:

  • Analysis of IL-2 activity in acidic tumor conditions.
  • Directed evolution to engineer a pH-selective IL-2 mutein (Switch-2).
  • Assessment of Switch-2's binding affinity, STAT5 activation, and T cell effector function in vitro and in vivo.

Main Results:

  • Tumor-generated lactic acid creates an acidic environment that inhibits IL-2 signaling, STAT5 activation, and CD8+ T cell antitumor immunity.
  • Switch-2 exhibits enhanced binding to IL-2Rα and potent T cell activation at acidic pH.
  • High-dose Switch-2 therapy promotes significant immune activation and tumor rejection with decreased toxicity.

Conclusions:

  • pH is a critical factor modulating IL-2 activity and efficacy in tumors.
  • Switch-2 represents a promising therapeutic strategy for enhancing cancer immunotherapy by overcoming acidic tumor microenvironments.
  • pH sensitivity is a generalizable feature of cytokines, impacting diverse immune processes and therapeutic applications.

Related Concept Videos